For Their Discovery of Human Immunodeficiency Virus

Total Page:16

File Type:pdf, Size:1020Kb

For Their Discovery of Human Immunodeficiency Virus 2008 NOBEL LAUREATES The Nobel Prize in Physiology or Medicine 2008 “for his discovery of “for their discovery human papilloma of human viruses causing immunodeficiency cervical cancer” virus” ) X X I I P P DKFZ SCAN SCAN AKUTIN/ AGUNIA/ S M DEUTSCHES KREBSFORSCHUNGSZENTRUM ( KREBSFORSCHUNGSZENTRUM DEUTSCHES Harald zur Hausen Françoise Luc Montagnier 1/2 of the prize Barré-Sinoussi 1/4 of the prize 1/4 of the prize Born: 1936 Born: 1932 Birthplace: Germany Born: 1947 Birthplace: France Nationality: German citizen Birthplace: France Nationality: French citizen Current position: Nationality: French citizen Current position: Professor Emeritus and Current position: Professor Emeritus and former Chairman and Professor and Director, Director, World Foundation Scientific Director, German Regulation of Retroviral for AIDS Research and Cancer Research Centre, Infections Unit, Virology Prevention, Paris, France Heidelberg, Germany Department, Institut Pasteur, Paris, France PHYSIOLOGY OR MEDICINE 13 Copyright © Nobel Web AB 2008. Nobelprize.org, Nobel Prize and the Nobel Prize medal design mark are registered trademarks of the Nobel Foundation. 2008 NOBEL LAUREATES Speed read: Finding the culprit identification of the virus associated with AIDS, occurred within just a few months amid a flurry of global research activity directed towards finding the cause of the then-new epidemic. Harald zur Hausen’s suggestion that human papilloma virus (HPV) infection might lie behind cervical cancer flew in the face of general opinion in the early 1970s, which held that another commonly present virus, herpes simplex virus, might be the cause. Realising that there were a multitude of different HPV subtypes, and hypothesising that unknown subtypes might cause the cancer, zur Hausen’s group began a painstaking search for such novel ooking back over the two discoveries rewarded viruses. By the early 1980s they found novel viruses with the 2008 Nobel Prize in Physiology in genital warts. Their subsequent identification of L or Medicine reveals two different timelines two novel HPV subtypes in cervical cancers formed for discovery research. One, Harald zur Hausen’s the essential piece of evidence linking HPV infection realisation that subtypes of a virus that produces to the onset of the disease. harmless warts can also lead to cervical cancer, took a decade of work to prove, initially against a Françoise Barré-Sinoussi and Luc Montagnier’s backdrop of considerable scepticism. The other, discovery of the virus that later came to be known Françoise Barré-Sinoussi and Luc Montagnier’s as human immunodeficiency virus (HIV) occurred zur Hausen identifies two new Harald zur Hausen publishes tumorigenic types of HPV in The first preventive HPV his first report attempting to cervical cancer biopsies – HPV16 vaccine is approved by the find human papilloma virus and HPV18 – and subsequently US Food and Drug Adminis- (HPV) DNA in cervical cancer shows that they are present in tration; two HPV vaccines are and genital wart biopsies the majority of cervical cancers currently on the market 1974 1976 1983–1984 1985 2006 zur Hausen and his zur Hausen demonstrates that parts of the team identify multiple, HPV DNA are integrated into the host genome previously undiscovered, in cervical cancer cell lines, providing an strains of HPV opening to study the role of the transferred viral DNA genes in malignant transformation Timeline: Milestones for the 2008 Nobel Laureate in Physiology or Medicine, Harald zur Hausen. 14 PHYSIOLOGY OR MEDICINE Copyright © Nobel Web AB 2008. Nobelprize.org, Nobel Prize and the Nobel Prize medal design mark are registered trademarks of the Nobel Foundation. 2008 NOBEL LAUREATES just two years after the first reports of cases of what we now know as AIDS. An infective agent was suspected by many to cause the disease, and Barré- Sinoussi and Montagnier decided to test whether it might be a so-called retrovirus. Retroviruses are relatively uncommon among the viruses that infect humans and rely on the host’s cellular machinery to replicate their RNA. The gamble proved correct; their studies revealed retroviral activity in cells taken from a patient’s lymph nodes, and demonstrated that viral particles from these cells could infect and kill white blood cells. Within the year, Barré- Sinoussi and Montagnier had isolated HIV from several patient groups. Soon afterwards several research groups provided convincing evidence that showed HIV to be the cause of AIDS. protection from the two HPV subtypes found in the majority of cervical cancer cases. Barré-Sinoussi Identifying the viral culprits behind two human and Montagnier’s discoveries led to a greater diseases that impact greatly on global health understanding of HIV and the way it interacts with provided crucial insights into the workings of each humans, allowing the development of diagnostic virus, which, in turn, led to the development of tools and a range of antiviral drugs aimed at much-needed treatments. zur Hausen’s discoveries controlling HIV, and with it providing hope that the enabled the development of vaccines that provide disease could eventually become treatable. April: Barré-Sinoussi and Montagnier isolate the virus and show it infects and A serious new medical kills lymphocytes from both diseased syndrome is described in An international virus and healthy patients, and reacts with California and New York, defined taxonomy consortium antibodies from infected patients as Acquired Immune Deficiency names the virus Human Syndrome (AIDS) by the US Jun–Oct: They obtain isolates of the virus Immunodeficiency Virus Centers for Disease Control from several patient groups type 1, or HIV-1 1981–1982 1983 1984 1984–1985 1985 Françoise Barré-Sinoussi and Luc Several research groups Montagnier detect activity from a new publish reports that help to type of retrovirus in cells cultured definitively show that the from the lymph nodes of patients virus causes AIDS showing early symptoms of AIDS Timeline: Milestones for the 2008 Nobel Laureates in Physiology or Medicine, Françoise Barré-Sinoussi and Luc Montagnier. PHYSIOLOGY OR MEDICINE 15 Copyright © Nobel Web AB 2008. Nobelprize.org, Nobel Prize and the Nobel Prize medal design mark are registered trademarks of the Nobel Foundation. 2008 NOBEL LAUREATES In his own words: Harald zur Hausen “I’m of course totally surprised. And it’s of course involved in this cancer, together with the fact that a great pleasure for me.” Sitting in his office at the so many questions remained unanswered about German Cancer Research Center, the news that papilloma viruses. “I was not from the beginning Harald zur Hausen had received the 2008 Nobel mainly interested in papilloma virus, I was mainly Prize in Physiology or Medicine had yet to fully sink in. interested in infectious agents in human cancer. Perhaps surprise is an apt response; for years, few Papilloma viruses came up as the most likely considered zur Hausen’s proposal, that cervical cancer candidate from my viewpoint.” was caused by the same virus that caused skin warts, worthy of serious discussion, let alone a Nobel Prize. The key breakthrough in finding that two subtypes of human papilloma virus, called HPV16 and 18, When zur Hausen first suggested publicly that human are found in most cervical cancer cases wasn’t papilloma virus, or HPV, caused cervical cancer at a automatically followed by the successful development meeting in Key Biscayne, Florida, in 1974, it flew in of vaccines, mainly because companies were the face of the prevailing view that the culprit was unconvinced that this was a worthwhile investment. herpes simplex virus. “It was As zur Hausen recalls, one not very welcome,” recalls zur “My statements were not German company showed some Hausen. “My statements were well received, and I felt as interest, but it pulled the plug not well received, and I felt as a on the project after carrying out lonely voice in that meeting.” a lonely voice” some damning market analysis. “According to this market When asked what gave him the dedication to analysis there would be no market for such a vaccine. persevere for years and eventually prove the link And then they stopped the funding.” between HPV and cervical cancer, zur Hausen responds that it was the combination of a personal Now the opposite appears to be the case; results conviction that there must be an infectious agent from trials on cervical cancer vaccines within the last decade have been enormously promising. zur Hausen sees this as clear evidence that vaccination programmes should be widened; however, he cautions that “The major disadvantage at this stage is that it is too expensive for those parts of the world which most badly need the CIENCE PHOTO LIBRARY CIENCE PHOTO S / vaccine; namely, the developing world.” UCT zur Hausen believes that scientists will discover more links between viruses and cancer, and he TANNARD, TANNARD, S is keen to promote greater interest in this line of research. “I hope, indeed, that this Nobel Prize will of course create more awareness of the role R LINDA R LINDA D of infectious agents in human cancer”. Having spent decades in pursuit of his goal, it is perhaps appropriate that he hadn’t rushed into making any plans for celebrating his Nobel Prize. Coloured transmission electron micrograph of “It was so surprising I really have to sleep about it human papilloma viruses (HPV). for one night or so before I make any decisions.” This article is based on a telephone interview with Harald zur Hausen following the announcement of the 2008 Nobel Prize in Physiology or Medicine. To listen to the interview in full, visit http://nobelprize.org/nobel_prizes/medicine/laureates/2008/hausen-interview.html 16 PHYSIOLOGY OR MEDICINE Copyright © Nobel Web AB 2008. Nobelprize.org, Nobel Prize and the Nobel Prize medal design mark are registered trademarks of the Nobel Foundation. 2008 NOBEL LAUREATES In her own words: Françoise Barré-Sinoussi isiting the Pasteur Institute in Cambodia, Françoise Barré-Sinoussi says she was unaware that she had been awarded the AVASSARD R V L Nobel Prize in Physiology or Medicine until a French radio journalist called her for an interview.
Recommended publications
  • An Update Review of Globally Reported SARS-Cov-2 Vaccines in Preclinical and Clinical Stages
    International Immunopharmacology 96 (2021) 107763 Contents lists available at ScienceDirect International Immunopharmacology journal homepage: www.elsevier.com/locate/intimp Review An update review of globally reported SARS-CoV-2 vaccines in preclinical and clinical stages Hamid Motamedi a, Marzie Mahdizade Ari b, Shirin Dashtbin b, Matin Fathollahi a, Hadi Hossainpour a, Amirhoushang Alvandi a,c, Jale Moradi a, Ramin Abiri a,d,* a Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran b Department of Microbiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran c Medical Technology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran d Fertility and Infertility Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran ARTICLE INFO ABSTRACT Keywords: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of the rapidly spreading COVID-19 pandemic COVID-19 in the world. As an effective therapeutic strategy is not introduced yet and the rapid genetic SARS-CoV-2 variations in the virus, there is an emerging necessity to design, evaluate and apply effective new vaccines. An Vaccines acceptable vaccine must elicit both humoral and cellular immune responses, must have the least side effects and the storage and transport systems should be available and affordable for all countries. These vaccines can be classified into different types: inactivated vaccines, live-attenuated virus vaccines, subunit vaccines, virus-like particles (VLPs), nucleic acid-based vaccines (DNA and RNA) and recombinant vector-based vaccines (repli­ cating and non-replicating viral vector). According to the latest update of the WHO report on April 2nd, 2021, at least 85 vaccine candidates were being studied in clinical trial phases and 184 candidate vaccines were being evaluated in pre-clinical stages.
    [Show full text]
  • Pandemic.Pdf.Pdf
    1 PANDEMICS: Past, Present, Future Published in 2021 by the Mahatma Gandhi Institute of Education for Peace and Challenges & Opportunities Sustainable Development, 35 Ferozshah Road, New Delhi 110001, India © UNESCO MGIEP This publication is available in Open Access under the Attribution-ShareAlike Coordinating Lead Authors: 3.0 IGO (CC-BY-SA 3.0 IGO) license (http://creativecommons.org/licenses/ ANANTHA KUMAR DURAIAPPAH by-sa/3.0/ igo/). By using the content of this publication, the users accept to be Director, UNESCO MGIEP bound by the terms of use of the UNESCO Open Access Repository (http:// www.unesco.org/openaccess/terms-use-ccbysa-en). KRITI SINGH Research Officer, UNESCO MGIEP The designations employed and the presentation of material throughout this publication do not imply the expression of any opinion whatsoever on the part of UNESCO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. The ideas and opinions expressed in this publication are those of the authors; they Lead Authors: NANDINI CHATTERJEE SINGH are not necessarily those of UNESCO and do not commit the Organization. Senior Programme Officer, UNESCO MGIEP The publication can be cited as: Duraiappah, A. K., Singh, K., Mochizuki, Y. YOKO MOCHIZUKI (Eds.) (2021). Pandemics: Past, Present and Future Challenges and Opportunities. Head of Policy, UNESCO MGIEP New Delhi. UNESCO MGIEP. SHAHID JAMEEL Coordinating Lead Authors: Director, Trivedi School of Biosciences, Ashoka University Anantha Kumar Duraiappah, Director, UNESCO MGIEP Kriti Singh, Research Officer, UNESCO MGIEP Lead Authors: Nandini Chatterjee Singh, Senior Programme Officer, UNESCO MGIEP Contributing Authors: CHARLES PERRINGS Yoko Mochizuki, Head of Policy, UNESCO MGIEP Global Institute of Sustainability, Arizona State University Shahid Jameel, Director, Trivedi School of Biosciences, Ashoka University W.
    [Show full text]
  • COVIPENDIUM Aug4.Pdf
    COVIPENDIUM Information available to support the development of medical countermeasures and interventions against COVID-19 Cite as: Martine DENIS, Valerie VANDEWEERD, Rein VERBEEKE, Anne LAUDISOIT, Tristan REID, Emma HOBBS, Laure WYNANTS & Diane VAN DER VLIET. (2020). COVIPENDIUM: information available to support the development of medical countermeasures and interventions against COVID-19 (Version 2020-08-04). Transdisciplinary Insights. This document is conceived as a living document, updated on a weekly basis. You can find its latest version at: https://rega.kuleuven.be/if/corona_covid-19. The COVIPENDIUM is based on open-access publications (scientific journals and preprint databases, communications by WHO and OIE, health authorities and companies) in English language. Please note that the present version has not been submitted to any peer-review process. Any comment / addition that can help improve the contents of this review will be most welcome. For navigation through the various sections, please click on the headings of the table of contents and follow the links marked in blue in the document. Authors: Martine Denis, Valerie Vandeweerd, Rein Verbeke, Anne Laudisoit, Tristan Reid, Emma Hobbs, Laure Wynants, Diane Van der Vliet COVIPENDIUM version: 04 AUG 2020 Transdisciplinary Insights - Living Paper | 1 Contents List of abbreviations .......................................................................................................................................................... 9 Introduction ...................................................................................................................................................................
    [Show full text]
  • Iran Hopes to Defeat COVID with Home-Grown Crop of Vaccines
    Q&A Iran hopes to defeat COVID with home-grown crop of vaccines Iran is one of few Middle Eastern nations to transfer money is restricted, it is difficult with the capacity to develop vaccines. It to buy drugs and medicines. And we have has been doing so in earnest: more than the technology to produce vaccines, so why ten are in development, but little is known not use it? To ensure the safety of Iranians, it about them outside Iran. Nature speaks makes sense to develop a variety of vaccines to Kayhan Azadmanesh, head of the using different research and development virology division at the Pasteur Institute of strategies, as China has done. Iran in Tehran, about the nation’s vaccine landscape. Azadmanesh also advises the Why are Iranian researchers reluctant to Iranian government and is developing publicize their work internationally? vaccines through his spin-off company This could be another effect of the sanctions. Humimmune Biotech. Researchers in Iran might not want to draw too much attention to their work in case they How badly has the pandemic affected Iran? put potential partnerships in jeopardy or they Since January 2020, we’ve had five waves. run the risk of losing access to raw materials. We’re currently experiencing the highest Researchers are also extremely busy number of new cases reported so far, with during the pandemic. But some have started MAJID ASGARIPOUR/WANA VIA REUTERS MAJID ASGARIPOUR/WANA around 40,000 a day, and the most common to share results. In June, the researchers variant we detect is Delta.
    [Show full text]
  • Accelerating Vaccination Against Covid-19
    Accelerating vaccination against Covid-19 Press release of the French National Academy of Medicine April 12, 2021 The major challenge in overcoming the current health crisis is to acquire a sufficient herd immunity to control the circulation of SARS-CoV-2 and to consider the relaxation of restriction measures. Two factors contribute to this collective immunity: the proportion of people who have been infected since the beginning of the pandemic, estimated at 20% of the French population, and the vaccination coverage, which has just exceeded 18% of adults for the first injection. Post-infectious immunity is based on neutralizing antibodies that persist for more than one year after a moderate or severe form of Covid-19, and 6 to 8 months after an asymptomatic form [1], but also on the cellular response of T lymphocytes. This observation has led the French High Authority for Health to recommend that vaccination of immunocompetent individuals with confirmed SARS-CoV-2 infection be delayed for 3 to 6 months after the infectious episode and reduced to a single dose [2]. The vaccination coverage rate to reach the control of the epidemic has been increased to take into account the increased transmissibility of the B.1.1.7 variant, known as "British", which has become predominant throughout metropolitan France. According to the Pasteur Institute's modelling, more than 90% of the adult population would need to be vaccinated to achieve this objective, as long as the vaccination of children is not foreseen [3]. These estimates reinforce the prospect of a sustained circulation of SARS-CoV-2, which may lead to the emergence of new variants, with deleterious consequences on public health and the country's economy.
    [Show full text]
  • MRC Centre for Outbreak Analysis and Modelling
    Centre for Outbreak Analysis and Modelling MRC Centre for ANNUAL REPORT Outbreak Analysis and Modelling www.imperial.ac.uk/medicine/outbreaks 2012 The Centre specialises in quantitative epidemiology encompassing mathematical modelling, statistical analysis and evolutionary epidemiology, to aid the control and Director’s message treatment of infectious diseases. April 2013 sees the Centre renewed for a second 5-year Consortium (led by Tim Hallett) and the Vaccine Modelling term, after we received an unprecedented 10 out of 10 Initiative – are up for renewal. However, grants are only score from the MRC subcommittee, which assessed the one aspect of the relationship. As important are the close performance of the Centre over its first term. Just as the working relationships between staff in the Centre and the work of the Centre over that time has been very much a Foundation, which sees our research increasingly used to team effort, so was the success of the renewal. inform Foundation strategy and delivery. The last few months have seen us start to drive through Despite its title, the Centre’s mission rapidly evolved to our strategy for the next 5 years. A crucial aspect of this encompass delivering innovative epidemiological analysis is to boost capacity in key research areas. It is therefore not only of novel infectious disease outbreaks, but also of my pleasure to welcome new academic staff into the endemic diseases of major global health significance. Our Centre. Xavier Didelot joined us last year as a lecturer in work on polio, malaria and HIV reflects this. However, the pathogen genetics, and our expertise in evolutionary and last few months have highlighted the ongoing relevance of genetic research will be further boosted this year by the our original mission to enhance preparedness and response recruitment of at least one additional member of academic to emerging disease threats.
    [Show full text]
  • News in Focus FEI/NYT/REDUX/EYEVINE SLAM YIK ​ Paramedics Transport a Man Thought to Be the First Person in Hong Kong to Have Contracted the New Coronavirus
    The world this week News in focus FEI/NYT/REDUX/EYEVINE SLAM YIK Paramedics transport a man thought to be the first person in Hong Kong to have contracted the new coronavirus. WHAT SCIENTISTS WANT TO KNOW ABOUT THE CORONAVIRUS OUTBREAK Researchers have sequenced the deadly pathogen’s genome — and are now rushing to find out how it spreads and how deadly it is. By Ewen Callaway and David Cyranoski Researchers fear similarities to the 2002–03 international concern — the agency’s highest epidemic of severe acute respiratory syn- level of alarm — after a meeting of officials last he world is racing to learn more about drome (SARS), which emerged in southern week, but that could change. the outbreak of a new viral infection that China and killed 774 people in 37 countries. Nature rounds up the questions at the heart was first detected in Wuhan, China, last Both are members of a large virus family, called of scientists’ efforts to understand the virus. month and is causing increasing alarm coronaviruses, that also includes viruses around the world. responsible for the common cold. How does the virus spread? TAs Nature went to press, officials in China China has taken unprecedented action to try This is the most urgent question surrounding had confirmed more than 4,500 cases of the to halt the outbreak — including putting Wuhan the outbreak. Chinese authorities have con- virus, which causes a respiratory illness, and and nearby cities on ‘lockdown’, restricting firmed that it spreads from person to person some 100 deaths. Around 50 cases had also travel in and out of the cities.
    [Show full text]
  • Special Edition - 5Th UPDATE 05/03/21
    IMMUNOWATCH Special edition - 5Th UPDATE 05/03/21 COVID-19 INTRODUCTION MabDesign and the COVID-19 pandemic The COVID-19 pandemic was matched by an unprecedented mobilisation of the French immunotherapy network and the pharmaceutical industry at large. Indeed, at the time of publication, three French companies already have preventive and/or therapeutic candidates currently undergoing Phase III clinical trials. In parallel, several bioprocessing sites across France have secured contracts for the production of both drugs and vaccines against SARS-CoV-2. These tremendous results were made possible through accelerated R&D as well as production and distribution logistics combined with facilitated access to information, resources and potential collaborators. MabDesign has been continuously adapting its actions and services to further support and enhance this nationwide pandemic response. Our latest and ongoing contribution to the fight against COVID-19 is through this special edition of Immunowatch and its regular updates. MabDesign’s Immunowatch is a one-of-a-kind information monitoring newsletter in the field of biomedicaments which aims at providing members of our association with the most recent and relevant data gathered or generated through the key expertise of MabDesign and its collaborators in scientific research, business intelligence, market analysis and intellectual property. Its original format has been modified to cater for the fast evolution of the response to the COVID-19 pandemic and allow rapid and pertinent updates. Immunowatch is done in collaboration with the MAbMapping Unit of the Ambition Recherche & Développement (ARD) Biomédicaments 2020 Phase II programme, funded by the Centre Val de Loire region. 2 Table of content 4.
    [Show full text]
  • Vaccines to Prevent Sars-Cov-2 Infection
    CORONAVIRUS DISEASE 2019 (COVID- 19):VACCINES TO PREVENT SARS-COV-2 INFECTION Dr Amitis Ramezani Head of Clinical Research group., Pasteur Institute of Iran Overview of vaccine development • Vaccines to prevent SARS-CoV-2 infection are considered the most promising approach for curbing the pandemic and are being vigorously pursued. As of winter 2020, several vaccines have become available for use in different parts of the world, over 40 candidate vaccines were in human trials, and over 150 were in preclinical trials. • When most people in a community are vaccinated against a disease, the ability of the pathogen to spread is limited. This is called ‘herd’ or ‘indirect’ or ‘population’ immunity. • When many people have immunity, this also indirectly protects people who cannot be vaccinated, such as very young babies and those who have compromised immune systems. • As with the development of pharmaceuticals, vaccine development progresses through preclinical evaluation and three distinct clinical stages, phases I, II, and III . Traditionally, these steps occur sequentially, and each usually takes several years for completion. SARS-CoV-2 vaccine development has accelerated to an unprecedented pace, with each step occurring over several months. Nevertheless, safety criteria remain stringent. • In the United States, the Food and Drug Administration (FDA) must approve progression to each next step in human trials, from initiation of phase I trials through progression to phase III trials. Steps in vaccine development Actions taken to ensure a
    [Show full text]
  • Close to the Edge: Co-Authorship Proximity of Nobel Laureates in Physiology Or Medicine, 1991 - 2010, to Cross-Disciplinary Brokers
    Close to the edge: Co-authorship proximity of Nobel laureates in Physiology or Medicine, 1991 - 2010, to cross-disciplinary brokers Chris Fields 528 Zinnia Court Sonoma, CA 95476 USA fi[email protected] January 2, 2015 Abstract Between 1991 and 2010, 45 scientists were honored with Nobel prizes in Physiology or Medicine. It is shown that these 45 Nobel laureates are separated, on average, by at most 2.8 co-authorship steps from at least one cross-disciplinary broker, defined as a researcher who has published co-authored papers both in some biomedical discipline and in some non-biomedical discipline. If Nobel laureates in Physiology or Medicine and their immediate collaborators can be regarded as forming the intuitive “center” of the biomedical sciences, then at least for this 20-year sample of Nobel laureates, the center of the biomedical sciences within the co-authorship graph of all of the sciences is closer to the edges of multiple non-biomedical disciplines than typical biomedical researchers are to each other. Keywords: Biomedicine; Co-authorship graphs; Cross-disciplinary brokerage; Graph cen- trality; Preferential attachment Running head: Proximity of Nobel laureates to cross-disciplinary brokers 1 1 Introduction It is intuitively tempting to visualize scientific disciplines as spheres, with highly produc- tive, well-funded intellectual and political leaders such as Nobel laureates occupying their centers and less productive, less well-funded researchers being increasingly peripheral. As preferential attachment mechanisms as well as the economics of employment tend to give the well-known and well-funded more collaborators than the less well-known and less well- funded (e.g.
    [Show full text]
  • Programme 70Th Lindau Nobel Laureate Meeting 27 June - 2 July 2021
    70 Programme 70th Lindau Nobel Laureate Meeting 27 June - 2 July 2021 Sessions Speakers Access Background Scientific sessions, Nobel Laureates, Clear guidance Everything else social functions, young scientists, to all viewing there is to know partner events, invited experts, and participation for a successful networking breaks moderators options meeting 2 Welcome Two months ago, everything was well on course to celebrate And yet: this interdisciplinary our 70th anniversary with you, in Lindau. anniversary meeting will feature But with the safety and health of all our participants being the most rich and versatile programme ever. of paramount importance, we were left with only one choice: It will provide plenty of opportunity to educate, inspire, go online. connect – and to celebrate! Join us. 4 PARTICIPATING LAUREATES 4 PARTICIPATING LAUREATES 5 Henry A. Joachim Donna George P. Hartmut Michael M. Adam Hiroshi Kissinger Frank Strickland Smith Michel Rosbash Riess Amano Jeffrey A. Peter Richard R. James P. Randy W. Brian K. Barry C. Dean Agre Schrock Allison Schekman Kobilka Barish John L. Harvey J. Robert H. J. Michael Martin J. Hall Alter Grubbs Kosterlitz Evans F. Duncan David J. Ben L. Edmond H. Carlo Brian P. Kailash Elizabeth Haldane Gross Feringa Fischer Rubbia Schmidt Satyarthi Blackburn Robert B. Reinhard Aaron Walter Barry J. Harald Takaaki Laughlin Genzel Ciechanover Gilbert Marshall zur Hausen Kajita Christiane Serge Steven Françoise Didier Martin Nüsslein- Haroche Chu Barré-Sinoussi Queloz Chalfie Volhard Anthony J. Gregg L. Robert J. Saul Klaus William G. Leggett Semenza Lefkowitz Perlmutter von Klitzing Kaelin Jr. Stefan W. Thomas C. Emmanuelle Kurt Ada Konstantin S.
    [Show full text]
  • Nobel Laureates in Physiology Or Medicine
    All Nobel Laureates in Physiology or Medicine 1901 Emil A. von Behring Germany ”for his work on serum therapy, especially its application against diphtheria, by which he has opened a new road in the domain of medical science and thereby placed in the hands of the physician a victorious weapon against illness and deaths” 1902 Sir Ronald Ross Great Britain ”for his work on malaria, by which he has shown how it enters the organism and thereby has laid the foundation for successful research on this disease and methods of combating it” 1903 Niels R. Finsen Denmark ”in recognition of his contribution to the treatment of diseases, especially lupus vulgaris, with concentrated light radiation, whereby he has opened a new avenue for medical science” 1904 Ivan P. Pavlov Russia ”in recognition of his work on the physiology of digestion, through which knowledge on vital aspects of the subject has been transformed and enlarged” 1905 Robert Koch Germany ”for his investigations and discoveries in relation to tuberculosis” 1906 Camillo Golgi Italy "in recognition of their work on the structure of the nervous system" Santiago Ramon y Cajal Spain 1907 Charles L. A. Laveran France "in recognition of his work on the role played by protozoa in causing diseases" 1908 Paul Ehrlich Germany "in recognition of their work on immunity" Elie Metchniko France 1909 Emil Theodor Kocher Switzerland "for his work on the physiology, pathology and surgery of the thyroid gland" 1910 Albrecht Kossel Germany "in recognition of the contributions to our knowledge of cell chemistry made through his work on proteins, including the nucleic substances" 1911 Allvar Gullstrand Sweden "for his work on the dioptrics of the eye" 1912 Alexis Carrel France "in recognition of his work on vascular suture and the transplantation of blood vessels and organs" 1913 Charles R.
    [Show full text]